FDA approves MRK’s Capvaxive—(f/k/a V116)—pneumococcal vaccine for adults: https://www.businesswire.com/news/home/20240614126575/en With this approval, MRK should finally get a decent share of the market for adult pneumococcal vaccines, where PFE’s Prevnar franchise has long been dominant. Please see #msg-173458310 and #msg-172452293 for related info.